Email this article 
Correlations Between Anti-SARS-CoV-2 Titers, CD4+ T-Cell Counts, and COVID-19 Severity
Abstract
Coronavirus disease 2019 (COVID-19) presents with diverse symptoms ranging from mild to severe. Patients with severe COVID-19 can show impaired humoral and cellular immunity and excessive pro-inflammatory cytokine production. Antibodies are generated against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) due to the activation of the humoral immune system. Molecular-based testing is currently used to diagnose COVID-19. Determining antibody and CD4+ T cell counts can help monitor the antibody response to assess the risk of reinfection and vaccine response. This study aimed to determine the relationships between Aanti-SARS-CoV-2 titer, CD4+ T cell count, and COVID-19 severity. This analytic observational study used a cross-sectional design with consecutive sampling and was conducted at RSUP Prof. Dr. R. D. Kandou Manado Hospital from April to October 2021. It comprised 48 patients with COVID-19. The data were compared using Spearman’s rank correlation coefficient (rs). Anti-SARS-CoV-2 titers were nonsignificantly correlated with COVID-19 severity (rs = 0.081, p = 0.582) and CD4+ T cell counts (rs = 0.214, p = 0.145). In contrast, CD4+ T cell counts were significantly negatively correlated with COVID-19 severity (rs = -0.454, p = 0.001). Anti-SARS-Cov-2 titers cannot be used as an indicator of COVID-19 severity. Moreover, CD4+ T cell counts cannot be used as a marker of anti-SARS-CoV-2 titers. However, COVID-19 severity correlates negatively with CD4+ T cell counts, indicating that CD4+ T cell counts can be used as an indicator of COVID-19 severity.
Keywords
Full Text:
PDFReferences
Afzal, N., Tariq, N., Raza, S., & Shakeel, D. (2021). Diagnostic Accuracy of Electro-Chemiluminescence Immunoassay Anti-SARS-CoV-2 Serological Test. Cureus, 13(1), 1–6.
Agra Bermejo, R., Cordero, A., García-Acuña, J. M., Gómez Otero, I., Varela Román, A., Martínez, Á., Álvarez Rodríguez, L., Abou-Jokh, C., Rodríguez-Mañero, M., Cid Álvarez, B., López-Palop, R., Carrillo, P., & González-Juanatey, J. R. (2018). Determinants and Prognostic Impact of Heart Failure and Left Ventricular Ejection Fraction in Acute Coronary Syndrome Settings. Revista Española de Cardiología (English Edition), 71(10), 820–828.
Bläckberg, A., Fernström, N., Sarbrant, E., Rasmussen, M., & Sunnerhagen, T. (2021). Antibody kinetics and clinical course of COVID-19 a prospective observational study. PLoS ONE, 16(3 March), 1–10.
Bonny, T. S., Patel, E. U., Zhu, X., Bloch, E. M., Grabowski, M. K., Abraham, A. G., Littlefield, K., Shrestha, R., Benner, S. E., Laeyendecker, O., Shoham, S., Sullivan, D., Quinn, T. C., Casadevall, A., Pekosz, A., Redd, A. D., & Tobian, A. A. R. (2021). Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma. Open Forum Infectious Diseases, 8(2), 1–10.
Bulut, C., & Kato, Y. (2020). Epidemiology of covid-19. Turkish Journal of Medical Sciences, 50(SI-1), 563–570.
Chvatal-Medina, M., Mendez-Cortina, Y., Patiño, P. J., Velilla, P. A., & Rugeles, M. T. (2021). Antibody Responses in COVID-19: A Review. Frontiers in Immunology, 12(April), 1–14.
Dieye, T. N., Diaw, P. A., Daneau, G., Wade, D., Sylla Niang, M., Camara, M., Diallo, A. A., Toure Kane, C., Diop Ndiaye, H., Mbengue, B., Dieye, A., Kestens, L., & Mboup, S. (2011). Evaluation of a flow cytometry method for CD4 T cell enumeration based on volumetric primary CD4 gating using thermoresistant reagents. Journal of Immunological Methods, 372(1–2), 7–13.
Haimovich, A. D., Ravindra, N. G., Stoytchev, S., Young, H. P., Wilson, F. P., van Dijk, D., Schulz, W. L., & Taylor, R. A. (2020). Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. Annals of Emergency Medicine, 76(4), 442–453.
Higgins, V., Fabros, A., & Kulasingam, V. (2021). Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: January, 1–7.
Hojyo, S., Uchida, M., Tanaka, K., Hasebe, R., Tanaka, Y., Murakami, M., & Hirano, T. (2020). How COVID-19 induces cytokine storm with high mortality. Inflammation and Regeneration, 40(1). https://doi.org/10.1186/s41232-020-00146-3
Koblischke, M., Traugott, M. T., Medits, I., Spitzer, F. S., Zoufaly, A., Weseslindtner, L., Simonitsch, C., Seitz, T., Hoepler, W., Puchhammer-Stöckl, E., Aberle, S. W., Födinger, M., Bergthaler, A., Kundi, M., Heinz, F. X., Stiasny, K., & Aberle, J. H. (2020). Dynamics of CD4 T Cell and Antibody Responses in COVID-19 Patients With Different Disease Severity. Frontiers in Medicine, 7(November), 1–10.
Kutsuna, S., Asai, Y., Matsunaga, A., & Kinoshita, N. (2021). Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19. 27(6), 808-13.
Lee, N., Jeong, S., Park, M. J., & Song, W. (2021). Comparison of three serological chemiluminescence immunoassays for SARS-CoV-2, and clinical significance of antibody index with disease severity. PLoS ONE, 16(6 June), 1–13.
Liu, J., Liu, Y., Xiang, P., Pu, L., Xiong, H., Li, C., Zhang, M., Tan, J., Xu, Y., Song, R., Song, M., Wang, L., Zhang, W., Han, B., Yang, L., Wang, X., Zhou, G., Zhang, T., Li, B., … Wang, X. (2020). Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. Journal of Translational Medicine, 18(1), 1–12.
Long, Q. X., Liu, B. Z., Deng, H. J., Wu, G. C., Deng, K., Chen, Y. K., Liao, P., Qiu, J. F., Lin, Y., Cai, X. F., Wang, D. Q., Hu, Y., Ren, J. H., Tang, N., Xu, Y. Y., Yu, L. H., Mo, Z., Gong, F., Zhang, X. L., … Huang, A. L. (2020). Antibody responses to SARS-CoV-2 in patients with COVID-19. Nature Medicine, 26(6), 845–848.
Mazzoni, A., Salvati, L., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Mencarini, J., Caporale, R., Peruzzi, B., Antonelli, A., Trotta, M., Zammarchi, L., Ciani, L., Gori, L., Lazzeri, C., Matucci, A., Vultaggio, A., Rossi, O., Almerigogna, F., … Cosmi, L. (2020). Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. Journal of Clinical Investigation, 130(9), 4694–4703.
Peng, X., Ouyang, J., Isnard, S., Lin, J., Fombuena, B., Zhu, B., & Routy, J. P. (2020). Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. Frontiers in Immunology, 11(December), 1–11.
Röltgen, K., Powell, A. E., Wirz, O. F., Stevens, B. A., Hogan, C. A., Najeeb, J., Hunter, M., Wang, H., Sahoo, M. K., Huang, C. H., Yamamoto, F., Manohar, M., Manalac, J., Otrelo-Cardoso, A. R., Pham, T. D., Rustagi, A., Rogers, A. J., Shah, N. H., Blish, C. A., … Boyd, S. D. (2020). Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Science Immunology, 5(54), 1–19.
Sun, J., He, W.-T., Wang, L., Lai, A., Ji, X., Zhai, X., Li, G., Suchard, M. A., Tian, J., Zhou, J., Veit, M., & Su, S. (2020). COVID-19: Epidemiology, Evolution, and Cross-Disciplinary Perspectives. January.
Wang, Q., Yao, Y., Huang, Z., Cao, J., Zhu, C., Yu, K., Pan, J., & Hu, B. (2021). Low CD4 T cell count predicts radiological progression in severe and critically ill COVID-19 patients: A case control study. Journal of Thoracic Disease, 13(8), 4723–4730.
Yan, X., Chen, G., Jin, Z., Zhang, Z., Zhang, B., He, J., Yin, S., Huang, J., Fan, M., Li, Z., Chen, F., Zeng, Y., Han, X., & Zhu, Y. (2022). Anti-SARS-CoV-2 IgG levels in relation to disease severity of COVID-19. Journal of Medical Virology, 94(1), 380–383.
DOI: https://doi.org/10.14421/biomedich.2026.151.1549-1553
Refbacks
- There are currently no refbacks.
Copyright (c) 2026 Edwin Hadinata, Eko Surachmanto, Paul N. Harijanto
Biology, Medicine, & Natural Product Chemistry |
|
